Claudia Gonzalez-Wiedmaier

Mrs. Claudia Gonzalez-Wiedmaier


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
XAXimena Aguilera
Ximena Aguilera
CGClaudia Gonzalez-Wiedmaier
Claudia Gonzalez-Wiedmaier
MAMauricio Apablaza
Mauricio Apablaza
PRPaola Rubilar
Paola Rubilar
GIGloria Icaza
Gloria Icaza
PVPablo A Vial
Pablo A Vial
Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.

10 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
LNLoreto Nuñez-Franz
Loreto Nuñez-Franz
Ramirez-Santana Ramirez-SantanaRamirez-Santana Ramirez-Santana
Ramirez-Santana Ramirez-Santana
PRPaola Rubilar
Paola Rubilar
CVCecilia Vial
Cecilia Vial
MAMauricio Apablaza
Mauricio Apablaza
XAXimena Aguilera
Ximena Aguilera
Background: Chile has achieved the highest coverage for vaccines against the SARS-CoV-2 virus worldwide. Objective: To assess the progression of immunity (natural and acquired by vaccine) in a cohort from two Chilean cities. Methods: Individuals (n = 386) who participated in three phases of population-based serial prevalence studies were included (2020–2021 and 2022). Presence of SARS-CoV-2 antibodies was measured in serum. Data including time of vaccination and type of vaccine received were analysed with descriptive statistics. Results: Seroprevalence was 3.6% in the first round and increased to 96.9% in the second and 98.7% in the third. In the third round, 75% of individuals who had received the basal full scheme were seropositive at 180 days or more since their last dose; 98% of individuals who received one booster dose were seropositive at 180 days or more, and 100% participants who received two boosters were seropositive, regardless of time since their last dose. Participants receiving mRNA vaccines had higher seroprevalence rates over time. Conclusions: The high vaccination coverage in Chile enabled the population to maintain high levels of antibodies. Vaccination boosters are essential to maintain immunity over time, which also depends on the type of vaccine administered.

26 September 2018 in Tecnología y ciencias del agua
Verified
Journal Article
Open access
DDDayana P. De-La-Vega
Dayana P. De-La-Vega
CGClaudia Gonzalez-Wiedmaier
Claudia Gonzalez-Wiedmaier
CEC.A Campos Y Escalante
C.A Campos Y Escalante
JGJaime Gállego
Jaime Gállego
MSMaurin Salamanca
Maurin Salamanca
LMLis Manrique-Losada
Lis Manrique-Losada
Revista Tecnología y Ciencias del Agua (TyCA) del Instituto Mexicano de Tecnología del Agua (IMTA)

23 July 2020 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
APArmando Peruga
Armando Peruga
XMXaviera Molina
Xaviera Molina
IDIris Delgado
Iris Delgado
IMIsabel Matute
Isabel Matute
AOAndrea Olea-Normandin
Andrea Olea-Normandin
XAXimena Aguilera
Ximena Aguilera
Objective To assess the national level of compliance with the Chilean comprehensive smoke-free legislation by observing healthcare facilities, education centres, government offices, hospitality venues and private workplaces, by type of area within workplaces and public places: enclosed, semiopen and open. Methodology In this cross-sectional observational study, we studied a national representative sample of 3253 venues obtained through a two-stage cluster sampling design. First, 57 municipalities were randomly selected, proportionally to the total number of venues of interest. Second, within each selected municipality, a maximum of 12 venues of each sector was selected systematically from a list of existing sites. We determined the non-compliance level by estimating the percentage of the visited venues where smoking was observed or suspected in banned areas of the premises. Results Smoking or suspicion thereof was not observed in any enclosed area of any establishment. However, smoking violations were observed in semiopen areas ranging from less than 0.5% of schools and healthcare centres to around 10% of hospitality venues or 23.0% of higher education centres. Smoking violations were also observed in outdoor areas of 6.7% and 1.6% of the health centres and schools, respectively. Discussion The stark contrast in compliance with the smoking ban between the enclosed areas and the semiopen areas may be a consequence of the complex definition of semiopen areas in the regulations. The study also reflects the need to improve the overall enforcement of the smoke-free law, particularly in universities and hospitality venues.

30 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
XAXimena Aguilera
Ximena Aguilera
JHJuan Hormazábal
Juan Hormazábal
CVCecilia Vial
Cecilia Vial
LCLina Jimena Cortes
Lina Jimena Cortes
CGClaudia Gonzalez-Wiedmaier
Claudia Gonzalez-Wiedmaier
PVPablo A Vial
Pablo A Vial
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

16 March 2025 in Toxics
Verified
Journal Article
Open access
PDF file
PRPaola Rubilar
Paola Rubilar
MAMacarena Hirmas Adauy
Macarena Hirmas Adauy
MAMauricio Apablaza
Mauricio Apablaza
CACamila Paz Awad
Camila Paz Awad
XMXaviera Molina
Xaviera Molina
Verónica IglesiasVerónica Iglesias
Verónica Iglesias
Arsenic chronic exposure, particularly in its inorganic form, represents a significant public health concern. This study was conducted in Arica, the northernmost city in the country, whose inhabitants have been exposed to inorganic arsenic both naturally through drinking water and anthropogenically due to a toxic waste disposal site. We explored changes in inorganic arsenic levels in a cohort of pregnant women and their children over a decade, identifying exposure trends and their determinants. We used data on arsenic exposure through maternal urine samples during pregnancy, collected by the Health Authority between 2013 and 2016 (measurement 1), and followed up with assessments of their children in 2023 (measurement 2). Temporal changes in inorganic arsenic concentration were analyzed using the Wilcoxon Signed-Rank test, and a mixed linear regression model was employed to determine which factors contributed to urinary inorganic arsenic levels. We did not observe significant differences in mean arsenic concentrations between the two-time points (p = 0.4026). The mixed linear regression model revealed that children consuming bottled water had 8.3% lower urinary inorganic arsenic concentrations than those drinking tap water (95% CI: −15.36 to −0.54%). Additionally, children from ethnic groups had 8.64% higher inorganic arsenic concentrations (95% CI: 0.49 to 17.5%), while those with caregivers with higher education showed a 13.67% reduction (95% CI: −25.06 to −0.56%). Despite mitigation efforts, these findings underscore the ongoing risk of inorganic arsenic exposure among vulnerable populations. They further emphasize the importance of addressing natural arsenic contamination in water and implementing targeted interventions to reduce disparities associated with socioeconomic and demographic factors.